
    
      This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and
      dose-exploration study of AMG 176 administered IV in subjects with relapsed or refractory
      multiple myeloma and subjects with relapsed or refractory acute myeloid leukemia The study
      will be conducted in four parts.
    
  